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Abstract: BACKGROUND Ultrasound evaluation of carotid intima-media thickness (cIMT) has been
extensively used for potentially improving cardiovascular (CV) risk stratification in several patients’
categories. Subjects with systemic lupus erythematosus (SLE) have been investigated by both imaging
and molecular biomarker approaches with contrasting results. Here, we focused on the role of osteopontin
(OPN) as biomarker of subclinical atherosclerosis associated with SLE. MATERIALS AND METHODS
Eighty females (age 18-65 years) affected by SLE and eighty age-matched healthy female controls without
a clinical history of CV disease underwent ultrasound evaluation of cIMT and blood sample assay of
high-sensitivity C-reactive protein (hs-CRP) and OPN. RESULTS Healthy controls and SLE patients
significantly differed for CV risk factors (ie, waist circumference, hypertension and dyslipidaemia) and
the inflammatory status. Noteworthy, an opposite association between cIMT and OPN was observed in
the two study groups. Whereas OPN was positively associated with mean cIMT (r = 0.364; P = 0.001)
in SLE patients, a negative correlation was found in healthy controls. Furthermore, in SLE patients
increased circulating levels of OPN were associated with the use of hydroxychloroquine and the positivity
for the anti-dsDNA autoantibodies. At linear regression analysis, only OPN remained independently
associated with cIMT also after adjustment for age, smoking pack-year, Heart SCORE, disease length
and steroid therapy length. CONCLUSIONS These results indicate that serum OPN levels were strongly
associated with subclinical atherosclerosis in patients with LES and it might be a useful CV biomarker
that requires additional validation in larger trials.
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Background: Ultrasound evaluation of carotid intima media thickness (cIMT) has been 
extensively used for potentially improving cardiovascular (CV) risk stratification in several 
patients’ categories. Subjects with systemic lupus erythematosus (SLE) have been investigated 
by both imaging and molecular biomarker approaches with contrasting results. Here, we 
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focused on the role of osteopontin (OPN) as biomarker of subclinical atherosclerosis 
associated with SLE. 
Materials and Methods: Eighty females (age 18–65 years) affected by SLE and eighty age-
matched healthy female controls without a clinical history of CV disease underwent ultrasound 
evaluation of cIMT and blood sample assay of high-sensitivity C-reactive protein (hs-CRP) and 
osteopontin (OPN). 
Results: Healthy controls and SLE patients significantly differed for CV risk factors (i.e. waist 
circumference, hypertension and dyslipidemia) and the inflammatory status. Noteworthy, an 
opposite association between cIMT and OPN was observed in the two study groups. Whereas 
OPN was positively associated with mean cIMT (r=0.364; p=0.001) in SLE patients, a negative 
correlation was found in healthy controls. Furthermore, in SLE patients increased circulating 
levels of OPN were associated with the use of hydroxychloroquine and the positivity for the 
anti dsDNA autoantibodies. At linear regression analysis, only OPN remained independently 
associated with cIMT also after adjustment for age, smoking pack-year, Heart SCORE, disease 
length and steroid therapy length. 
Conclusions: These results indicate that serum OPN levels were strongly associated with 
subclinical atherosclerosis in patients with LES and it might be a useful CV biomarker that 
requires additional validation in larger trials. 
 
Keywords: systemic lupus erythematosus, carotid intima media thickness, C-reactive protein, 
osteopontin, and atherosclerosis 
.
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Introduction 
Dysregulation of immune response have been described in all stages of atherosclerosis, from 
early fatty streak development to vulnerable plaques erosion/rupture [1]. Systemic 
inflammatory diseases, such as systemic lupus erythematosus (SLE), are closely associated with 
an accelerated atherosclerosis and substantial epidemiological data attribute to cardiovascular 
(CV) diseases the excess mortality observed in those patients [2]. Nevertheless, this association 
is only partially due to SLE itself. Both immunosuppressive treatments and different classes of 
autoantibodies (e.g. antiphospholipid antibodies) might actively contribute to the increased CV 
risk [3]. SLE should be considered as an independent CV risk factor and the rate of acute events 
in those patients is two-fold higher than estimated by traditional risk models (i.e. Framingham 
and ACC/AHA scores) [4, 5]. On this basis, patients with SLE would generally benefit from 
additional CV screening and more intensive prevention strategies [6, 7]. To estimate subclinical 
atherosclerosis, different non-invasive approaches have been used, including carotid intima 
media thickness (cIMT), pulse wave velocity, and myocardial perfusion strategies [8]. Among 
those approaches, ultrasound evaluation of cIMT is one of the most used for risk stratification 
in SLE patients, being characterized by a high sensitivity [9] and with a high predictive value for 
adverse CV events [10, 11]. Conversely, the majority of biomarkers are burdened by low 
predictive value. Although biomarkers still require validation and their measurement might be 
quite expensive, these molecules have been shown to improve the longitudinal prediction of 
atherosclerotic plaques in SLE patients [12]. Traditionally known for the role in bone 
homeostasis, osteopontin (OPN) is increasingly emerging as biomarker of vascular 
inflammation [13]. With this aim, the present study was designed to test the potential role of 
OPN as a promising biomarker of subclinical atherosclerosis associated with SLE in a previously 
published cohort [14]. 
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Material and methods 
Patients and clinical assessment 
Eighty females (aged 18–65 years) affected by SLE and followed as outpatients were enrolled 
in the present sub-study, as previously described [14]. All subjects fulfilled the diagnostic 
criteria of the American College of Rheumatology for diagnosis of SLE [15] and were in inactive 
stage of the disease defined as SLE disease activity index score ≤4 [16]. Eighty age-matched 
healthy females were the enrolled as controls. None of subjects (both cases and controls) had 
an history of clinical CV or cerebrovascular events defined as angina, myocardial infarction, 
transient ischemic attack or ischemic stroke. For all subjects, physical examination, laboratory 
tests and structured interview were performed. In addition, traditional CV risk factors and 
family history for CV events were recorded, as previously described [14]. The Ethics Committee 
of Ospedale Policlinico San Martino (Genoa, Italy) approved this protocol, performed in 
accordance to the guidelines of the Declaration of Helsinki. Patients gave informed consent 
before entering in the study. 
 
Study endpoints and power estimation 
The primary outcome of the study is to determine whether circulating OPN values 
independently correlate with the extent of cIMT in SLE patients. Due to the small sample size 
and the absence of previous studies investigating the subset of patients with  SLE, the results 
concerning the primary outcome should be considered as part of “pilot” study. Nevertheless, 
the sample size is in line with previous studies investigating the relationship between OPN and 
cIMT in other autoimmune systemic inflammatory diseases [17-19]). 
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Ultrasonography measure 
All subjects underwent B-mode ultrasonography of extracranial carotid arteries using a 7.5 
MHz probe which provides a direct and non-invasive assessment of subclinical atherosclerosis 
through IMT measurement, as previously described [14]. Right and left common carotid 
arteries were scanned longitudinally and the common carotid artery IMT (CCA-IMT) 
measurement was taken 1.0 cm proximal to the carotid bulb, as in this point we have the 
maximum distance between the intima-lumen and the adventitia-media interfaces in areas 
without carotid plaque [20]. The cIMT image was then “frozen,” and stored for offline analysis. 
Offline cIMT measurements were performed with the M Ath Demo software (Version 2.0.1.0, 
by Metris, Argenteuil, France). 
 
Serum biomarker measurement 
Serum levels of OPN and high-sensitivity C-reactive protein (hs-CRP) were measured by 
colorimetric enzyme-linked immunosorbent assay, following manufacturer’s instructions (R&D 
Systems, Minneapolis, MN). The limits of detection were 62.5 pg/mL for OPN and 15.63 pg/mL 




Analyses were performed with IBM SPSS Statistics for Windows, Version 23.0 (IBM CO., 
Armonk, NY). Categorical data are presented as relative and absolute frequencies and analysed 
by Fisher’s exact test. Continuous variables were expressed as median (interquartile range 
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[IQR] and analysed with Mann-Whitney test as the normality assumption was not 
demonstrated. Correlations were analysed through the Spearman Rank correlation test. 
Finally, multiple linear regressions were then performed to model the CCA-IMT with the serum 




Characteristics of the overall cohort 
Baseline characteristics of the whole cohort (n=160) and the two study groups were listed in 
Supplementary Table 1 and 2. These characteristics implement the already published clinical 
variables of the cohort [14].  As expected given the young median age (41 years), patients 
showed low CV risk as calculated by the Heart Score. However, patients with SLE were 
characterized by increased waist circumference, blood pressure and dyslipidemia. In line with 
the high levels of classical inflammatory biomarkers (i.e. ESR and hs-CRP), also circulating value 
of OPN were increased in SLE patients (median value 16.9 vs. 25.0 ng/mL, p<0.001) 
(Supplementary Table 1, Figure 1A and 1B).  
 
OPN is differently associated with CCA-IMT in patients with SLE and healthy controls 
CCA-IMT was detectable in both right and left common carotid arteries, despite the low CV risk 
profile (young women). As previously shown in the same cohort for mean CCA-IMT [14], 
patients with SLE were characterized by an increased right and left values CCA-IMT as 
compared to healthy controls (p<0.001 for all) (Figure 1C-1D). Nevertheless, a positive 
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correlation between CCA-IMT and traditional CV risk factors (i.e. age, BMI, waist 
circumference, systolic blood pressure and SCORE Risk) was observed in the both study groups 
(p<0.05 for all) (Table 1). 
Unexpectedly, opposite associations between CCA-IMT and OPN was observed in the two 
study groups. Serum OPN was negatively associated with right (p=0.002), left (p=0.003) and 
mean (p=0.001) CCA-IMT in healthy controls (Figure 2A, 2C and 2E). Conversely, a positive 
correlation in SLE patients was observed for right (p=0.004), left (p=0.008) and mean (p=0.014) 
CCA-IMT (Figure 2B, 2D and 2F). Instead, hs-CRP failed to show any significant correlation with 
CCA-IMT in the two study groups. (Supplementary Figure 1A-1F). 
 
Serum OPN is positively associated with the inflammatory status and CCA-IMT in SLE patients 
In SLE patients, circulating levels of OPN were positively correlated with blood press values and 
inflammatory status, assessed by ESR and fibrinogen (Table 2). Furthermore, high circulating 
levels of OPN were associated with the use of hydroxychloroquine and the positivity for the 
anti dsDNA autoantibodies (Supplementary Table 3). When linear regression analysis was 
performed, serum OPN was significantly associated with right, left and mean CCA-IMT 
alongside with age and CV risk assessed by the  Heart Score risk (Table 3). However, OPN 
remained the only variable independently associated with CCA-IMT in the adjusted analysis for 
age, smoking pack-year, Heart SCORE, disease length and steroid therapy length (Table 3). 
Discussion 
We showed that serum levels of OPN, but not hs-CRP, were associated to CCA-IMT (a marker 
of subclinical atherosclerosis) in patients with SLE. Furthermore, the association between 
serum OPN and cIMT remained significant also after adjustment for age, smoking, Heart 
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SCORE, disease length and steroid therapy length. Except for this latter, no other classical CV 
risk factor demonstrated a relevant association with cIMT in SLE patients. The young age of the 
cohort of women should be taken into account to potentially explain this finding [14]. 
Furthermore, the characteristics of the study cohort we investigated young women (with SLE 
or healthy controls) might potentially explain the opposite association between OPN and CCA-
IMT observed in the two study groups. Despite speculative, it is likely that in healthy young 
women OPN does not reflect an increased CV risk (atherosclerosis is expected to be very 
initial), but rather a response to hormonal or  environmental factors [23-26]. Conversely, the 
strong positive association between OPN and CCA-IMT observed in patients further indicates 
SLE as a surrogate of a more advanced CV disease independently of age [27]. In this context, 
OPN would act as an active pro-atherosclerotic factor, as previously suggested [13]. 
On this basis, OPN emerges as potential biomarker of atherosclerosis in SLE. Traditionally 
known for the role in bone homeostasis, OPN is emerging as promising biomarker of vascular 
inflammation and atherogenesis [28]. Also, OPN has been widely recognized as predictor of 
atherosclerotic plaque rupture in cohorts of patients with severe carotid atherosclerosis [13, 
29, 30]. OPN is constitutively expressed by macrophages/foam cells and sustains pro-
inflammatory environment within atherosclerotic plaque by exerting an autocrine/paracrine 
activity [31]. Specifically, OPN contributes to macrophage chemotaxis, activation, survival and 
pro-inflammatory M1 polarization, in addition to promote neutrophil recruitment and 
activation [13, 32]. As an additional mechanism, OPN has been demonstrated to regulate 
interferon-I response, which has a role in both pathophysiology of SLE and subclinical 
atherosclerosis [33, 34]. Despite highly speculative, available data indicate OPN not only as an 
innocent biomarker, but rather an active mediator of plaque vulnerability. Similarly, both 
circulating and intraplaque expression of hs-CRP have been associated with atherosclerotic 
plaque rupture and the occurrence of adverse CV events [35, 36]. However, clinical studies 
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failed to clearly demonstrate hs-CRP as a useful biomarker of CV risk in patients with SLE [37-
40]. Even, abnormally low levels of CRP have been observed in active SLE [41]. This partial 
discrepancies as compared to the general population may be due to formation of anti-CRP 
autoantibodies, as reported in about 35 to 40% of patients with SLE [42]. In addition, a role of 
CRP polymorphisms has been hypothesized [43]. Conversely, OPN has been already described 
as reliable biomarker of subclinical atherosclerosis in other systemic inflammatory diseases, 
such as rheumatoid arthritis [17] and psoriasis [18, 19]. Growing data also indicate an active 
role of OPN in SLE pathophysiology. Genetic polymorphisms of OPN have been associated with 
disease activity [44, 45]. This may due to a potential role of OPN variants in developing 
autoimmune response by inducing Th1 responses and potentiating polyclonal activation of B 
cells [46]. Future studies may establish whether targeting OPN might modify the natural 
history of both SLE and related atherosclerosis. We acknowledge that the present study have 
some limitations. Due to the small sample size of this cohort, a result overestimation has to be 
carefully considered and no definite conclusions can be stated. However, our cohort was 
already validated [14] and the sample size is in line with previous studies [17-19]. Similarly, the 
ultrasonography method to measure cIMT has been widely published  and known to be 
partially dependent on the operator and the methods [14]. Nevertheless, meta-analyses 
clearly established the increase of cIMT in SLE patients, independent of ultrasonography 
method [9, 47].  
 
Conclusions 
The present study indicates circulating OPN as a sensible biomarker of subclinical 
atherosclerosis in patients with SLE. As compared with serum levels of hs-CRP, OPN correlates 
with cIMT independently of traditional CV risk factors or SLE-related variables. Although no 
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conclusive statements can be formulated, the assessment of serum OPN (alone, or eventually 
included in a panel of combined biomarkers) might be suggested as a useful tool to implement 
CV risk stratification in patients with SLE  
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Figure 1. Box plot comparing healthy controls and patients with systemic lupus 
erythematosus (SLE). Mann-Whitney test comparing high-sensitivity C-reactive protein (hs-
CRP) (A), osteopontin (OPN) (B) and right (C), and left (D) of common carotid artery-intima 
media thickness (CCA-IMT) in healthy controls and patients with SLE. 
 
Figure 2. Spearman’s Rank correlation. Serum concentrations of osteopontin (OPN) 
correlate with right (A and B), left (C and D) and mean values (E and F) of common carotid 
artery-intima media thickness (CCA-IMT), negatively in healthy controls and positively in SLE 
patients.  
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Table 1. Correlation of common carotid artery intima media thickness 
(CCA IMT) in the two study groups. 
 
 Right CCA IMT  Left CCA IMT  Mean CCA IMT 
Healthy controls         
Age 0.539 <0.001  0.512 <0.001  0.574 <0.001 
Weight 0.189 0.101  0.207 0.069  0.213 0.063 
BMI 0.238 0.037  0.248 0.028  0.260 0.022 
Waist circumference 0.321 0.004  0.325 0.004  0.343 0.002 
sBP 0.303 0.007  0.341 0.002  0.322 0.004 
dBP 0.124 0.283  0.187 0.102  0.163 0.156 
Smoking pack-year  0.004 0.973  0.122 0.288  0.069 0.554 
SCORE Risk Chart 0.274 0.016  0.287 0.011  0.301 0.008 
Fasting glycaemia 0.072 0.531  0.217 0.057  0.160 0.166 
Total cholesterol 0.095 0.410  0.195 0.087  0.151 0.189 
HDL 0.094 0.414  0.014 0.902  0.057 0.625 
LDL -0.096 0.406  0.036 0.757  -0.034 0.767 
TAG 0.069 0.549  0.229 0.044  0.155 0.177 
SLE         
Age 0.394 <0.001  0.414 <0.001  0.422 <0.001 
Weight 0.013 0.912  0.113 0.330  0.092 0.424 
BMI 0.125 0.276  0.195 0.089  0.177 0.123 
Waist circumference 0.115 0.316  0.164 0.154  0.166 0.148 
sBP 0.166 0.147  0.224 0.050  0.29 0.056 
dBP 0.153 0.182  0.206 0.072  0.185 0.108 
Smoking pack-year  0.215 0.059  0.211 0.066  0.239 0.036 
SCORE Risk Chart 0.290 0.010  0.303 0.007  0.328 0.004 
SLE duration 0.260 0.021  0.144 0.210  0.212 0.064 
Steroid therapy length 0.205 0.072  0.171 0.137  0.200 0.081 
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Fasting glycaemia -0.115 0.325  -0.223 0.056  -0.179 0.127 
Total cholesterol 0.042 0.717  -0.007 0.953  -0.004 0.972 
HDL 0.100 0.382  -0.044 0.706  -0.023 0.840 
LDL -0.028 0.756  0.107 0.354  0.091 0.429 
TAG -0.036 0.756  0.107 0.354  0.091 0.429 
 
Comparisons were drawn by Spearman Rank correlation test. 
 
BMI: body mass index; sBP: systolic blood pressure; dBP: diastolic blood pressure; 
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TAG: triglyceride. 
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Table 2. Correlation between osteopontin (OPN) and clinical parameters in 
the subgroups of SLE patients. 
 
 OPN 
 r p-value 
Age 0.108 0.186 
Weight -0.060 0.465 
BMI 0.059 0.475 
Waist circumference 0.070 0.392 
sBP 0.156 0.055 
dBP 0.243 0.003 
Smoking pack-year 0.052 0.647 
SCORE Risk Chart 0.136 0.097 
Disease length 0.085 0.453 
Steroid therapy length 0.151 0.180 
ESR 0.398 <0.001 
Fibrinogen 0.355 <0.001 
Fasting glycaemia 0.159 0.054 
Total cholesterol 0.009 0.913 
HDL 0.094 0.253 
LDL -0.053 0.520 
TAG 0.106 0.194 
 
Comparisons were drawn by Spearman Rank correlation test. 
 
BMI: body mass index; sBP: systolic blood pressure; dBP: diastolic blood pressure; 
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TAG: triglyceride. 
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Table 3. Linear regression analysis in the subgroup of patients with SLE. 
 
 Univariate  Adjusted  
  p-value  p-value 
Right CCA IMT     
OPN 0.323 0.004 0.291 0.008 
Age 0.278 0.014 0.240 0.028 
Smoking pack-year  0.160 0.163 - - 
Heart SCORE 0.218 0.055 - - 
Disease length 0.181 0.113 - - 
Steroid therapy length 0.140 0.220 - - 
Left CCA IMT     
OPN 0.299 0.008 0.256 0.017 
Age 0.370 0.001 0.266 0.044 
Smoking pack-year  0.159 0.166 - - 
Heart SCORE 0.317 0.005 0.127 0.332 
Disease length 0.108 0.349 - - 
Steroid therapy length 0.178 0.122 - - 
Mean CCA IMT     
OPN 0.280 0.014 0.240 0.027 
Age 0.342 0.002 0.232 0.083 
Smoking pack-year  0.190 0.097 0.084 0.503 
Heart SCORE 0.307 0.007 0.141 0.291 
Disease length 0.149 0.196 - - 
Steroid therapy length 0.165 0.151 - - 
 
CCA IMT: common carotid artery intima media thickness; OPN: osteopontin. 
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